Sun exposure and vitamin D are independent risk factors for CNS demyelination.

What Was Tested

The paper reports a study of Vitamin D, K2, Magnesium and Zinc, published as a randomized controlled trial.

Exposures measured included self-reported sun exposure by life stage, objective measures of skin phenotype and actinic damage, and vitamin D status.

Who Took Part

By PubMed's age tags, the people studied were teenagers, young adults, adults and middle-aged adults, both men and women.

How the Study Was Run

The design is described as randomized and multicenter.

Because people in this Vitamin D, K2, Magnesium and Zinc study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Running at several centres spread the Vitamin D, K2, Magnesium and Zinc study over different clinics and patient groups.

This was a multicenter incident case-control study.

Cases (n = 216) were aged 18-59 years with a FDE and resident within one of 4 Australian centers (from latitudes 27°S to 43°S), from November 1, 2003, to December 31, 2006.

Controls (n = 395) were matched to cases on age, sex, and study region, without CNS demyelination.

What Was Measured

Topics PubMed links to this paper include Case-Control Studies, Demyelinating Diseases, Multiple Sclerosis, Risk Factors, South Australia, Sunlight and Tasmania.

What This Means in Plain Language

The paper is a randomized and multicenter study of Vitamin D, K2, Magnesium and Zinc.

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2011 (Neurology), a journal based in United States.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.